| Gene symbol | CD86 | Synonyms | B7-2, B7.2, B70, CD28LG2, LAB72 | Type of gene | protein-coding |
| Chromosome | 3 | Map location | 3q13.33 | dbXrefs | |
| Description | CD86 molecule | ||||
| Gene symbol | PDCD1 | Synonyms | CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 | Type of gene | protein-coding |
| Chromosome | 2 | Map location | 2q37.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | programmed cell death 1 | ||||
| GTO ID | GTC3394 |
| Trial ID | NCT05801783 |
| Disease | Ovarian Cancer | Peritoneal Carcinomatosis | Fallopian Tube Cancer |
| Altered gene | CD86|PDCD1 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | R130 |
| Phase | Early_Phase1 |
| Recruitment status | Recruiting |
| Title | A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer |
| Year | 2023 |
| Country | China |
| Company sponsor | Shanghai Yunying Medical Technology |
| Other ID(s) | SHSY-R130-OC |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||
|
|||||||||